3 Chronic Therapy, Blue Pigment and Pizza Chain Stocks With a Strong Future Roadmap: Mankind Pharma, Ultramarine & Pigments and Jubilant FoodWorks

Chronic therapy, blue pigment and pizza chain stocks give investors exposure to medicines, colourants and food outlets used every day. Volumes, store additions and margins decide how much of that demand turns into profit.

Readers comparing chronic therapy, blue pigment and pizza chain stocks should weigh growth, margins, cash flow and valuation together instead of leaning on any single number.

This list covers three chronic therapy, blue pigment and pizza chain stocks: Mankind Pharma for branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, Ultramarine & Pigments for ultramarine blue pigments and related colourants for plastics, paints and detergents and Jubilant FoodWorks for Domino's Pizza stores across India and neighbouring markets, along with newer food brands. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Chronic Therapy, Blue Pigment and Pizza Chain Stocks?

Chronic therapy, blue pigment and pizza chain stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Chronic Therapy, Blue Pigment and Pizza Chain Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three chronic therapy, blue pigment and pizza chain stocks as of the 14 Oct 2026 close.

Among healthcare, chemicals and consumer stocks, Mankind Pharma trades at a premium to the industry P/E, while Ultramarine trades at a discount.

Why Do Chronic Therapy, Blue Pigment and Pizza Chain Stocks Have a Strong Roadmap in India?

Chronic therapy, blue pigment and pizza chain stocks have a strong roadmap in India because rising chronic care needs, detergent and paint output and eating out keep adding volumes for these firms. Three drivers stand out.

• Chronic care: Doctors prescribe more long-term therapies.
• Industrial colour: Detergents, plastics and paints use pigments.
• Eating out: Quick-service outlets reach more towns.

Mankind Pharma: Branded Formulations Anchor the Roadmap

Mankind Pharma's roadmap rests on branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, with a broad brand portfolio supporting prescriptions and sales.

Revenue grew from Rs 7,977.58 crore in FY22 to Rs 14,636.43 crore in FY26, an 83.5% rise, and FY26 revenue was 14.8% higher than FY25. FY26 net profit was Rs 1,938.10 crore. In Q1 FY27, revenue grew 11.7% to Rs 4,075.59 crore, and net profit rose 29.1% to Rs 574.09 crore. Operating margin was 27.06% in FY26 and 27.42% in Q1 FY27 against 26.04% a year earlier.

Debt to equity is 0.39 and return on equity is 11.74%. FY26 operating cash flow was Rs 3,121.29 crore against capital expenditure of Rs 737.24 crore. Mankind Pharma paid a dividend of Rs 1 per share for FY26, a yield of 0.04%. At a P/E of 47.91 against an industry P/E of 37.59, the stock trades above its industry multiple.

What to watch: Q1 FY27 operating margin was 27.42% against 27.06% for FY26, so margin stability is the figure to follow as volumes grow.

Ultramarine & Pigments: Pigments for Plastics and Paints Drive the Pipeline

Ultramarine's roadmap rests on ultramarine blue pigments and related colourants for plastics, paints and detergents, with steady industrial demand supporting volumes.

Revenue grew from Rs 499.48 crore in FY22 to Rs 786.41 crore in FY26, a 57.4% rise, and FY26 revenue was 11.2% higher than FY25. FY26 net profit rose 7.6% to Rs 80.77 crore. Over four years, net profit rose from Rs 58.30 crore in FY22 to Rs 80.77 crore. In Q1 FY27, revenue grew 31.2% to Rs 245.68 crore, and net profit rose 56.5% to Rs 31.59 crore. Operating margin was 17.91% in FY26 and 21.33% in Q1 FY27 against 18.78% a year earlier.

Debt to equity is 0.10 and return on equity is 9.29%. FY26 operating cash flow was Rs 128.27 crore against capital expenditure of Rs 67.87 crore. Ultramarine paid a dividend of Rs 6 per share for FY26, a yield of 1.50%. At a P/E of 12.67 against an industry P/E of 36.60, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 21.33% against 17.91% for FY26, so margin stability is the figure to follow as volumes grow.

Jubilant FoodWorks: Domino's Store Network Anchors the Roadmap

Jubilant FoodWorks' roadmap rests on Domino's Pizza stores across India and neighbouring markets, along with newer food brands, with store additions and delivery reach supporting sales.

Revenue grew from Rs 4,437.48 crore in FY22 to Rs 9,586.64 crore in FY26, a 116.0% rise, and FY26 revenue was 17.2% higher than FY25. FY26 net profit rose 54.4% to Rs 386.03 crore. In Q1 FY27, revenue grew 13.6% to Rs 2,588.34 crore, and net profit rose 6.0% to Rs 100.03 crore. Operating margin was 20.96% in FY26 and 20.37% in Q1 FY27 against 20.21% a year earlier.

Debt to equity is 2.14 and return on equity is 18.69%. FY26 operating cash flow was Rs 1,893.55 crore against capital expenditure of Rs 1,009.93 crore. Jubilant FoodWorks paid a dividend of Rs 1.2 per share for FY26, a yield of 0.28%. At a P/E of 62.77 against an industry P/E of 61.79, the stock trades in line with its industry multiple.

What to watch: Debt to equity of 2.14 is on the higher side, and net profit margin is only 4.0%, so small cost changes move earnings.

Best Chronic Therapy, Blue Pigment and Pizza Chain Stocks in India: Mankind Pharma vs Ultramarine vs Jubilant FoodWorks on Key Financials

Among the best chronic therapy, blue pigment and pizza chain stocks in India, Mankind Pharma leads on FY26 operating margin; Ultramarine leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; Jubilant FoodWorks leads on FY26 revenue growth and return on equity. The table puts the numbers side by side.

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Chronic Therapy, Blue Pigment and Pizza Chain Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen chronic therapy, blue pigment and pizza chain stocks and shortlist chronic therapy, blue pigment and pizza chain stocks to buy.

1. Compare each stock's P/E with its industry P/E, which differs by company here.
2. Check revenue growth, operating margin and cash flow together.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these chronic therapy, blue pigment and pizza chain stocks

Risks to Consider Before Investing in Chronic Therapy, Blue Pigment and Pizza Chain Stocks

• Debt and cash flow: Jubilant FoodWorks has debt to equity of 2.14.
• Consumer demand: Spending patterns can shift sales between quarters.
• Input costs: Changes in raw material prices can affect margins.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Mankind Pharma, Ultramarine and Jubilant FoodWorks live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare, chemicals and consumer stocks cover branded medicines, pigments and quick-service restaurants. Mankind Pharma leads on FY26 operating margin; Ultramarine leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; Jubilant FoodWorks leads on FY26 revenue growth and return on equity.

Across chronic therapy, blue pigment and pizza chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the chronic therapy, blue pigment and pizza chain stocks to buy discussed here.

FAQs on Chronic Therapy, Blue Pigment and Pizza Chain Stocks

Which are the best chronic therapy, blue pigment and pizza chain stocks in India with a strong roadmap?

Ans. Mankind Pharma, Ultramarine & Pigments and Jubilant FoodWorks stand out for their roadmaps in branded medicines, pigments and quick-service restaurants. FY26 revenue growth was 14.8% at Mankind Pharma, 11.2% at Ultramarine and 17.2% at Jubilant FoodWorks, and return on equity ranges from 9.29% to 18.69%.

Is Mankind Pharma a good stock to buy now?

Ans. Mankind Pharma has a debt to equity ratio of 0.39, a return on equity of 11.74% and a P/E of 47.91 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Mankind Pharma, Ultramarine and Jubilant FoodWorks?

Ans. The P/E ratio is 47.91 for Mankind Pharma (industry 37.59), 12.67 for Ultramarine (industry 36.60) and 62.77 for Jubilant FoodWorks (industry 61.79). Only Mankind Pharma and Jubilant FoodWorks trade at or above the industry multiple.

Which of these chronic therapy, blue pigment and pizza chain stocks has the highest return on equity?

Ans. Jubilant FoodWorks has the highest return on equity at 18.69%, followed by Mankind Pharma at 11.74% and Ultramarine & Pigments at 9.29%.

What are the risks of investing in chronic therapy, blue pigment and pizza chain stocks?

Ans. The main risks are debt and cash flow, consumer demand, input costs and quarterly trends. Jubilant FoodWorks has debt to equity of 2.14.

How did Mankind Pharma, Ultramarine and Jubilant FoodWorks perform in Q1 FY27?

Ans. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. Ultramarine & Pigments reported revenue of Rs 245.68 crore, up 31.2% year on year, and net profit rose 56.5% to Rs 31.59 crore. Jubilant FoodWorks reported revenue of Rs 2,588.34 crore, up 13.6% year on year, and net profit rose 6.0% to Rs 100.03 crore.

Do chronic therapy, blue pigment and pizza chain stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.04% for Mankind Pharma, 1.50% for Ultramarine and 0.28% for Jubilant FoodWorks, based on dividends declared for FY26.

How can I invest in chronic therapy, blue pigment and pizza chain stocks in India?

Ans. You can buy chronic therapy, blue pigment and pizza chain stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.